Foamix Settles Litigation With Perrigo On Finacea Foam

(RTTNews) - Foamix Pharmaceuticals Ltd. (FOMX) said Tuesday that, together with LEO Pharma, it has settled the Hatch-Waxman litigation with Perrigo, relating to Finacea Foam. Terms of the settlement are not disclosed.

Foamix is the owner of patents that have been licensed to LEO Pharma to market Finacea Foam, a topical prescription medicine used to treat the inflammatory papules and pustules of mild to moderate rosacea.

Foamix's lead development candidates, FMX101 and FMX103, are based on a different foam technology platform and different patents than those listed in the Orange Book for the foam technology used in Finacea.

As required by law, the companies will submit the settlement agreement to the U.S. Federal Trade Commission and the U.S. Department of Justice for review.

Patent infringement litigations related to Finacea Foam continue against Teva Pharmaceuticals USA, Inc. and Taro Pharmaceuticals U.S.A. and Taro Pharmaceutical Industries, Ltd.